Description
Patients with leiomyosarcoma or liposarcoma that are metastatic or unresectable after undergoing a previous anthracycline-containing therapy are treated with Trabectedin Injection, an alkylating drug.
Trabectedin
- Medicine Name- Trabec natco
- API- Trabectedin
- Packaging- 1 Single-dose vial
- Strength- 1mg
- Manufactured by- Natco
Dosage and Side Effects
In patients with normal bilirubin levels and AST or ALT levels less than or equal to 2.5 times the upper limit of normal, the standard dose of Trabectedin is 1.5 mg/m2. This medication should be given as an intravenous infusion over 24 hours through a central venous line every three weeks or 21 days, until the disease progresses or unacceptable toxicity occurs.
Constipation, nausea, exhaustion, decreased appetite, peripheral edoema, vomiting, diarrhoea, dyspnea, and headache are among the side effects of trabectedin that are frequently observed.
Warning and Precautions
- Give the intravenous dexamethasone dosage of 20 mg half an hour before to each Trabectedin dose.
- Patients who have severe allergy to trabectedin, including anaphylaxis, should not take 1 mg of trabectedin.
- Before each Trabectedin dose is administered and subsequently on a recurring basis during the course of treatment, the neutrophil count must be evaluated.
- Examine LFTs prior to each injection of trabectedin. Depending on the degree and length of the LFT anomaly, manage the increased LFTs by stopping therapy, reducing the dose, or permanently stopping the medication.
- Evaluate the left ventricular ejection fraction (LVEF) with an echocardiography or MUGA (Multigated Acquisition) scan before starting trabectedin and then every two to three months until the medication is stopped.
- When given to a pregnant woman, trabectedin injection has the potential to harm the foetus due to its mode of action.
- Nursing women are recommended to stop nursing while on trabectedin medication due to the possibility of serious side effects in breastfed infants.
FAQ's
What is Trabectedin?
In particular, Trabectedin is an anticancer chemotherapy drug used to treat ovarian cancer and advanced soft-tissue sarcoma.
How should 0.25 mg of Trabectedin be administered?Â
The recommended method of administration for Trabectedin 0.25 mg is intravenous infusion.Â
Who should not receive Trabectedin?Â
If you have experienced a severe allergic reaction to trabectedin, you will not be administered trabectedin.
Related products
-
Azacitidine Tablets 200MG & 300MG tablets
-
Antithymocyte Globulin-Equine 250 mg Injection
-
Atracurium Besylate 25MG/2.5 mL Injection
-
Semaglutide
